Comparative Pharmacology
Head-to-head clinical analysis: LIVTENCITY versus XOFLUZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVTENCITY versus XOFLUZA.
LIVTENCITY vs XOFLUZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
Baloxavir marboxil is a prodrug that is converted to baloxavir acid, which inhibits the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein, thereby preventing viral mRNA transcription and replication.
200 mg orally once daily with food.
40 mg orally once as a single dose; for patients weighing ≥80 kg, 80 mg orally once as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
The terminal elimination half-life of baloxavir marboxil is approximately 79.1 hours (range 53–107 hours), supporting single-dose therapy for influenza.
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Baloxavir marboxil is primarily excreted via feces (80.1%) and urine (14.7%) after oral administration, with <1% as unchanged drug in urine.
Category C
Category C
Antiviral
Antiviral